Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00705120 · ClinicalTrials.gov registry record · Phase 1
Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
A Phase 1 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00705120 is a Phase 1 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 9 participants.
The verdict
NCT00705120, a Phase 1 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This protocol was a prospective, Phase I study of allogeneic bone marrow transplantation (BMT) as the primary therapy for Osteogenesis Imperfecta Types II and III. Compatible sibling donors and unrelated donors were stratified and analyzed according to the type of donor. All patients with a sibling donor will received a chemotherapy conditioning regimen; a non-T cell depleted allogeneic marrow, and GVHD prophylaxis. All patients with an unrelated donor will receive a chemoradiotherapy conditioning regimen, a T-cell depleted allogeneic marrow, and GVHD prophylaxis. The primary objective of this study was to investigate the safety and toxicity of these BMT procedures in this particular population.
Interventions
- DRUG Cyclophosphamide
- PROCEDURE Mesenchymal Stem Cell Transplantation
- DRUG Cyclosporin
- OTHER Bone Marrow Cell Transplantation
- RADIATION Irradiation, Total Body
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 1995-11 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00705120
The ClinicalTrials.gov registry entry for NCT00705120 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00705120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00705120 about?
NCT00705120 is a clinical study titled "Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation". This protocol was a prospective, Phase I study of allogeneic bone marrow transplantation (BMT) as the primary therapy for Osteogenesis Imperfecta Types II and III. Compatible sibling donors and unrelated donors were stratified and analyzed according to the type of donor. All patients with a sibling ...
What is the current status of trial NCT00705120?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 1995-11. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00705120?
The interventions under investigation include: Cyclophosphamide (DRUG), Mesenchymal Stem Cell Transplantation (PROCEDURE), Cyclosporin (DRUG), Bone Marrow Cell Transplantation (OTHER), Irradiation, Total Body (RADIATION).
Who is sponsoring clinical trial NCT00705120?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.